Good, even great news, but if we're just 'starting' with mice-models now, we're looking at a 5-10 year runway before 'market-access' is a reality...
The IIQ upside might be that the 'diagnostic' EXO-products become revenue streams far mor quickly (less capital-intensive on SHs, limited CRs), being that they're not IV/IT administered into patients... (eg: no potential adverse side-effects)
Biotech is a long, slow road, stay tuned I guess...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
36.5¢ |
Change
-0.005(1.35%) |
Mkt cap ! $40.74M | |||
| Open | High | Low | Value | Volume |
| 37.0¢ | 37.0¢ | 36.5¢ | $21.43K | 58.25K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 6522 | 36.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 38.0¢ | 3500 | 1 |
View Market Depth
| Last trade - 16.10pm 28/07/2025 (20 minute delay) ? |
| IIQ (ASX) Chart |